Anti-trka antibodies, derivatives and uses thereof

Abstract

The present invention relates to an antibody, recombinant or synthetic antigen-binding fragments thereof able to recognise and bind an epitope comprised in the TrkA amino acid sequence, medical uses thereof and a pharmaceutical composition comprising at least one of the above antibody, recombinant or synthetic antigen-binding fragments thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This patent application is a continuation of U.S. application Ser. No. 13 / 894,489, filed on May 15, 2013, that in turn claims benefit of priority from European Patent Application No. 12171752.4, filed Jun. 13, 2012, the contents of all of which are incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention relates to anti-TrkA antibodies and to derivatives thereof which are able to recognise and bind an amino acid sequence comprised in the Nerve Growth Factor NGF-binding site of the high affinity tyrosine kinase receptor of NGF (TrkA), thus acting as NGF antagonists and preventing the functional activation of TrkA by NGF. The antibodies of the invention are useful in the treatment of conditions associated with the expression and / or activity of TrkA, including pain states.BACKGROUND OF THE INVENTIONMonoclonal Antibodies.[0003]Monoclonal antibodies (Mabs) represent the fastest-growing market segment within the pharmac...

AI Technical Summary

Benefits of technology

This patent describes a new antibody that can neutralize the action of NGF, a protein that is associated with pain and inflammation. The antibody can be used to treat diseases such as cancer and neuropathic pain. The dosage and treatment duration will depend on the specific disease being treated. The antibody can also be combined with other treatments to reduce the risk of unwanted side effects. Overall, this new technology provides a promising tool to develop new treatments for pain and inflammation related diseases.

Problems solved by technology

However, this antibody was found to be a TrkA agonist and therefore not useful for inhibiting TrkA-triggered activities and consequently having a therapeutic effect, as reducing pain.

As a matter of fact, when binding to TrkA, this antibody does not prevent the functional activation of the receptor, since, on the contrary, it induces the receptor functional activation upon its binding.

Persistent pain represents a major health problem.

However, they are associated with gastrointestinal toxicity, and although COX-2-selective inhibitors have significantly reduced adverse gastric effects, there is still a raised risk of cardiovascular disease (Zeilhofer, 2007.

Nonetheless, corticosteroids display remarkable adverse effects including weight gain, insomnia, and immune system weakening.

However, long-term use of opiates is limited by several serious drawbacks, including development of tolerance and physical dependence (Przewlocki and Przewlocka, 2001.

Images